Boehringer Ingelheim confirms BioWhittaker agreement:
This article was originally published in Clinica
Executive Summary
Boehringer Ingelheim has confirmed it will buy BioWhittaker's interest in the companies' joint venture for cell culture products in Verviers, Belgium (see Clinica No 653, p 13). Under the recently signed agreement, Boehringer Ingelheim says it intends to integrate the joint venture into its affiliated distributors in Spain, Austria and Germany. However, until the restructuring takes place, BioWhittaker will maintain its exclusive distribution arrangements in those countries. BioWhittaker has also agreed to sell to the joint venture its distribution subsidiary in France. Its UK subsidiary will continue to be the joint venture's exclusive distributor in the UK and Ireland. BioWhittaker has the option to repurchase its interest in the venture for an agreed price over a designated period.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.